Study of Retifanlimab and Ruxolitinib for Certain Cancers
Treatments studied
Part of Cancer, Kidney & urinary, Lungs & breathing, Women’s health & pregnancy clinical trials.
This trial tests a combination of two drugs, retifanlimab and ruxolitinib, for people with advanced kidney cancer (clear cell renal cell carcinoma) or lung cancer (non-small cell lung carcinoma) whose cancer has grown after previous treatment with a type of immunotherapy called PD-1/PD-L1 inhibitors. The goal is to see if this combination can help when standard treatments are no longer working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced kidney cancer (clear cell) or lung cancer (non-small cell) that has grown despite prior treatment with a PD-1/PD-L1 immunotherapy drug.
- You have declined or exhausted standard treatment options for your cancer.
- You are able to take oral medications and follow the study schedule.
- You have not been treated before with a Janus kinase (JAK) inhibitor drug (like ruxolitinib).
- You have not had more than one prior line of PD-1/PD-L1 therapy, and your best response to that therapy was stable disease, partial shrinkage, or complete disappearance of the cancer (not progression).
- You do not have uncontrolled infections, active autoimmune disease requiring steroids, or untreated brain metastases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether combining envafolimab (an anti-immune cancer medicine) with lenvatinib (a targeted pill) can shrink or control advanced cancers that have stopped responding to standard care. It may help people whose tumors are not curable with usual treatments, by testing a new combo and finding safe doses.
This study tests a new combination of two drugs (L19IL2 and ruxolitinib) for people with advanced solid tumors, specifically pancreatic, colorectal, or kidney cancer that has grown after standard treatments. The goal is to see if this combination is safe and may help shrink tumors.
This trial is testing two drugs, pembrolizumab and ruxolitinib, together for people with certain types of lymphoma that have come back or not responded to at least one prior treatment. The goal is to see if this combination can help control the lymphoma.
This trial tests new treatments for people with stage IV nonsquamous non-small cell lung cancer that has gotten worse after prior immunotherapy and chemotherapy. It aims to find better options for those whose cancer has specific genetic features.
This study tests a new combination of medicines for people with advanced clear cell kidney cancer that has gotten worse after first treatment. The combination includes two immunotherapy drugs (iparomlimab and tuvonralimab) plus one of two targeted therapy pills (lenvatinib or axitinib). The goal is to see if this approach can help control the cancer.
This trial tests a new combination of two drugs, ruxolitinib and ulixertinib, for people with myelofibrosis whose disease is not fully controlled by ruxolitinib alone. The goal is to see if adding ulixertinib can improve spleen enlargement, symptoms, or bone marrow changes.
Hear when a new Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.